PB 19 of 2026

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2026 (No. 2)

 

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 98C(1) of the National Health Act 1953.

Dated 26 February 2026

REBECCA RICHARDSON
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division

Contents

1. Name

2. Commencement

3. Authority

4. Schedules

Schedule 1—Amendments

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1. The whole of this instrument

1 March 2026

1 March 2026

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)

[1] Schedule 4, after entry for Apremilast

insert:

Aripiprazole

Powder for injection 300 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe

Aripiprazole

Powder for injection 400 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe

[2] Schedule 4, after entry for Hypromellose with dextran

insert:

IncobotulinumtoxinA

Lyophilised powder for injection 100 units

[3] Schedule 4, after entry for Pimecrolimus

insert:

Pioglitazone

Tablet 15 mg (as hydrochloride), pack of 30

Pioglitazone

Tablet 30 mg (as hydrochloride), pack of 30

Pioglitazone

Tablet 45 mg (as hydrochloride), pack of 30

[4] Schedule 4, omit entry for Silver sulfadiazine